INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies—Established Findings and Future Priorities

Ligon, John A.; Ramakrishna, Sneha; Ceppi, Francesco; Calkoen, Friso G.J.; Diorio, Caroline; Davis, Kara L.; Jacoby, Elad; Gottschalk, Stephen; Schultz, Liora M.; Capitini, Christian M.

doi:10.1016/j.jtct.2023.10.012

Transplantation and Cellular Therapy

2024

DOI: 10.1016/j.jtct.2023.10.012

|View full text |Cite

INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies—Established Findings and Future Priorities

John A. Ligon,

Sneha Ramakrishna,

Francesco Ceppi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy

Dandoy,

Adams,

Artz

et al. 2024

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy

Dandoy,

Adams,

Artz

et al. 2024

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations

Perna,

Parekh,

Diorio

et al. 2024

Blood Advances

View full text Add to dashboard Cite

Multiple chimeric antigen receptor (CAR) T cell therapies are FDA approved, and several are under development. While effective for some cancers, toxicities remain a limitation. The most common toxicities, i.e. cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS), are well described. With increasing utilization, providers worldwide are reporting on other emergent, and often complicated toxicities. Given the evolving toxicity profiles and urgent need to catalogue these emerging and emergent CAR T toxicities and describe management approaches, the American Society of Hematology Subcommittee on Emerging Gene and Cell Therapies organized the first Scientific Workshop on CAR T cell toxicities during the annual society meeting. The workshop functioned to 1) aggregate reports of CAR T emergent toxicities, including movement disorders after BCMA CAR T, coagulation abnormalities, and prolonged cytopenias; 2) disseminate bedside to bench efforts elucidating pathophysiological mechanisms of CAR-T toxicities, including the intestinal microbiota and systemic immune dysregulation; and 3) highlight gaps in the availability of clinical tests such as cytokine measurements, which could be utilized to expand our knowledge around the monitoring of toxicities. Key themes emerged. First, while clinical manifestations may develop before the pathophysiologic mechanisms are understood, these must be studied to aid in the detection and prevention of such toxicities. Second, systemic immune dysregulation appears central to these emergent toxicities and research is needed to elucidate links between tumor, CAR T, and microbiota. Finally, there was consensus around an urgency to create a repository to capture emergent CAR-T toxicities and the real-world management.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies—Established Findings and Future Priorities

Cited by 2 publications

References 130 publications

In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy

In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy

CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations

Contact Info

Product

Resources

About